67.50 -0.24 (-0.35%)
Pre-market: 4:00AM EDT
|Bid||66.92 x 3000|
|Ask||67.64 x 1800|
|Day's range||67.63 - 69.48|
|52-week range||60.14 - 84.00|
|PE ratio (TTM)||10.39|
|Earnings date||8 Aug 2018|
|Forward dividend & yield||2.00 (2.85%)|
|1y target est||86.80|
Zacks Industry Outlook Highlights: Becton and Dickinson, Johnson & Johnson, Cigna and CVS Health
CVS Health Corporation (NYSE:CVS) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In theRead More...
While the world focused on the shares of media companies after a federal judge approved AT&T's (T) proposed $85 billion acquisition of Time Warner (TWX), other industries also benefited from the prospects of mega-deals. As Barron's Varada Bhat wrote, the S&P 500's top-performing stocks on Wednesday were either already involved in merger activities, or those that might be. Pharmacy chain CVS Health (CVS) announced plans to acquire Aetna (AET) for $69 billion in December.
Court approval of the AT&T-Time Warner deal now makes it more likely that similar kinds of pending mergers will go through — and there’s a good investing angle in this. The green light in the deal appears to clear the way for CVS Health’s (CVS) planned acquisition of insurer Aetna (AET), and Cigna’s (CI) pending takeover of pharmacy-benefit manager (PBM) Express Scripts (ESRX).
A federal judge's ruling late Tuesday blessing the AT&T-Time Warner merger raised hopes that the CVS-Aetna and Cigna-Express Scripts deals will win antitrust approval.
Health insurers and pharmacy-benefit managers with a rash of billion-dollar deals on the line are likely breathing sighs of relief after AT&T Inc. won clearance to takeover Time Warner Inc. The long-awaited green-light bodes well for CVS Health Corp.’s proposed $68 billion acquisition of health insurer Aetna Inc. and Cigna Corp.’s $54 billion deal for Express Scripts Holding Co., according to analysts. Investors were concerned the tie-ups may be challenged by the U.S. Department of Justice as both mergers received “second request” notifications, Matt Borsch, an analyst at BMO Capital Markets, wrote in a note to clients.
U.S. Health and Human Services Secretary Alex Azar told lawmakers that it may be time to eliminate the complex system of rebates that drug companies and pharmacy-benefit managers use to negotiate and set prices. Once drugmakers set a list price for a product, pharmacy-benefit managers like CVS Health Corp. and Express Scripts Holding Co. negotiate rebates. The PBMs have been criticized for keeping some of the rebates for themselves instead of passing them directly to consumers to lower their out-of-pocket costs.
CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.
CVS Health Corp. announced early Wednesday the management team that will serve once its acquisition of health insurer Aetna Inc. closes. Aetna Chief Financial Officer Shawn Guertin will serve as CVS Health's ...
CVS Health Corporation (NYSE:CVS) delivered an ROE of 17.24% over the past 12 months, which is an impressive feat relative to its industry average of 13.74% during the same period.Read More...
CVS Health (CVS) and Walgreens Boots Alliance (WBA) shares have seen high levels of volatility in the past year. Walgreens, which is currently trading at $62.70 as of May 29, has seen its share price move between $61.56 to $83.89 in the last 12 months. CVS is trading at $64.80. CVS has a 52-week price range of $60.14–$84.
Walgreens Boots Alliance (WBA) and CVS Health (CVS) are both well-covered stocks. While Walgreens is tracked by 27 analysts, 25 analysts cover CVS.
Currently, Walgreens Boots Alliance (WBA) and CVS Health (CVS) are valued below their historical averages. Walgreens stock trades around 10.2x the next 12-month earnings. Walgreens stock touched the lower end of its 52-week forward PE range of 10.1x–15.8x. The stock’s three-year average PE ratio is even higher at 16x.
CVS Health Corp. is buying Aetna Inc., while Cigna Corp. is snapping up Express Scripts Holding Co. As health-care companies vertically integrate with high-priced deals across varied parts of the industry’s supply chain, Walgreens Boots Alliance Inc.(WBA) , its acquisition of rival Rite Aid’s (RAD)nearly 2,000 stores now complete, remains alone at the party. See: U.S. health care is changing in a big way.
Drugstore stocks have been under pressure in the past year due to fears of Amazon (AMZN) entering the pharma space, President Trump’s drug pricing policy change, and the ongoing consolidation wave in the industry.
Walgreens Boots Alliance (WBA) and CVS Health (CVS) are two well-known pharmacy giants. The two pharmacy giants control at least half of the market share in 70 of the top 100 metropolitan areas, according to research by Barclays. One of the pharmacies has a higher level of vertical integration, while the other pharmacy has a more significant international presence.
According to my firm’s performance tracking, it is one of the best-performing investment newsletters over the long term, beating the broad U.S. stock market by a large margin. Indeed, at the beginning of January, Wright’s valuation model found that, among the 244 stocks he monitored, there were twice as many overvalued as undervalued stocks.
A habit of safe thinking has been sinking General Electric for years. Since John Flannery took the helm last June, GE(GE) at every turn has shown a preference for incremental solutions, avoiding risk and averting its gaze from the massive changes its businesses face. In 2017, when activist investors finally lost patience with Jeffrey Immelt, they replaced him with Flannery, the classic company man.
CVS Health’s recent acquisition of Aetna has sparked talk of a pharmacy of the future, in which CVS’s walk-in “minute clinics” offer more services, and in a more accessible way than traditional health care. Bertolini, who has previously compared this goal to Apple’s (AAPL) Genius Bar, said CVS stores and services could become a “tent without walls,” by say, encouraging an individual with Type 1 diabetes named Sally to exercise a certain amount and keep her hemoglobin levels below a certain point.
TripAdvisor (TRIP) reported its first-quarter results on May 10. Its revenue grew 1.6% to $378 million and surpassed the consensus estimate by 4.6%. It reported a drastic increase in earnings to $0.30 per share compared to EPS (earnings per share) of $0.24 in the first quarter of 2017. Its EPS also surpassed the consensus estimate of $0.16 per share. The stock rose 24.2% last week.
Managed-care organizations showed healthy upside in the first quarter, but the biggest story in MCO-land remains, of course, the upcoming CVS Health (CVS) acquisition of Aetna (AET). Credit Suisse analyst A.J. Rice in a Monday research report lowered his Aetna target to $194 from $208 but remains Neutral on the stock. "We use a 70% probability that the AET-CVS deal is approved ($197 deal price based on current CVS price).